Payload– tag –
-
SpaceX Falcon 9 Achieves 165 Missions in 2025, Normalizing Reusable Rocket Operations
Space Daily USA Overview SpaceX's Falcon 9 rocket successfully flew 165 orbital missions in 2025, demonstrating the full integration of reusable rocket technology into routine space operations. The Falcon 9 became the most frequently flo... -
SpaceX Starship Prepares for 13th Test Flight to Re-Attempt Booster Separation and Controlled Landing
Mashable USA Overview SpaceX is set to re-attempt the 13th test flight of its Starship system on July 24, 2026, after previous attempts were aborted due to engine ignition issues and weather. The primary objective of this flight is to va... -
FDA Approves Dato-DXd (Datroway) for Metastatic Triple-Negative Breast Cancer based on Phase III TROPION-Breast02 Trial
Cancer Network USA Overview The U.S. FDA has approved datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 immune check... -
Lonza and Engitix Ink ADC License Deal for ECM-Targeted Cancer, Fibrosis Therapies
GEN (Genetic Engineering & Biotechnology News) Switzerland Overview Lonza and Engitix Ltd. have signed a licensing agreement for an Antibody-Drug Conjugate (ADC) technology platform, targeting cancer and fibrosis therapies focused on the... -
Akari Therapeutics and Whitehawk Therapeutics Partner on Trop2-Targeting ADC AKTX-101, Leveraging Novel PH1 Payload for Immune Activation
Markets Insider USA Overview Akari Therapeutics has entered a strategic research collaboration with Whitehawk Therapeutics to advance its next-generation Antibody-Drug Conjugate (ADC) lead candidate, AKTX-101. AKTX-101 targets the Trop2 ... -
Optometrists Crucial for Ophthalmic Management of ADC Patients, Understanding Individualized Monitoring Requirements
Optometry Times USA Overview An Optometry Times article underscores the critical role of optometrists in the ophthalmic management of cancer patients undergoing Antibody-Drug Conjugate (ADC) therapy. Given that each ADC agent has unique ... -
Model-Optimized Bispecific Antibodies: A Novel Strategy to Enhance ADC Tumor Selectivity
Academia.edu USA Overview Research from Academia.edu elucidates the potential of computationally optimized bispecific antibodies (BsAbs) to enhance the tumor selectivity of Antibody-Drug Conjugates (ADCs). As ADC efficacy remains constra... -
Antibody-Drug Conjugates Evolve from ‘Magic Bullet’ to Standard of Care in Solid Tumors, T-DXd and Combination Therapies Set New Benchmarks
Binaytara USA Overview Antibody-Drug Conjugates (ADCs) have significantly evolved in solid tumor treatment, transitioning from a 'magic bullet' concept to a 'standard of care.' Globally, over 12 ADCs are approved, with more than 300 in c... -
Novartis Reverses ADC Holdout with $1.5B Myricx Deal Amid Sustained M&A Boom in ADC Market
Fierce Biotech USA Overview Novartis, previously hesitant about Antibody-Drug Conjugates (ADCs), has committed up to $1.5 billion to Myricx Bio, signaling a strategic shift into the burgeoning ADC market. This move follows a series of hi... -
Antibody-Drug Conjugates Evolve into Smart Chemotherapy, Datroway Gains FDA Approval for Metastatic Triple-Negative Breast Cancer
Karchem Consulting USA Overview Antibody-Drug Conjugates (ADCs) are evolving into next-generation 'smart chemotherapies' by integrating precise targeting with innovative linker-payload technologies. Novel drug classes like nucleic acid a...
